Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib dose-finding study of BYL719 plus imatinib in previously treated advanced GIST
NL-OMON40177Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alpelisib and imatinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Primary endpoints: Maximum tolerated dose and Recommended phase II dose. Started Apr 2013; status: active, not recruiting.
02
Drugs
alpelisibimatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON40177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40177.